Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Stuart Barnes

Internal Medicine Anderson, SC Medical Doctor

NPI 1114106325 CMS profile 187012

1100 W Franklin St, Anderson, SC 29624

Open in the dashboard

General payments

$3,562

212 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Stuart Barnes of Anderson, SC is reported in the CMS Open Payments database as having received $3,562 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,105 63
2022 General $1,014 69
2021 General $717 39
2020 General $34 2
2019 General $691 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stuart Barnes
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stuart Barnes were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stuart Barnes Internal Medicine median Middle half National median
2019 $691 $159 $48–$570 $163
2020 $34 $119 $33–$402 $114
2021 $717 $135 $37–$521 $132
2022 $1,014 $141 $42–$496 $149
2023 $1,105 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $566 40 payments
  2. Amgen Inc. $402 16 payments
  3. AstraZeneca Pharmaceuticals LP $382 20 payments
  4. Novo Nordisk Inc $344 23 payments
  5. Pfizer Inc. $211 14 payments
  6. Novartis Pharmaceuticals Corporation $151 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $148 9 payments
  8. Janssen Pharmaceuticals, Inc $120 7 payments
  9. GlaxoSmithKline, LLC. $114 8 payments
  10. AbbVie, Inc. $111 7 payments
  11. Other $1,013 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,562 212 payments
Products named General payments · program years 2019–2023
  1. Repatha $402 16 payments
  2. MOUNJARO $322 19 payments
  3. RYBELSUS $275 19 payments
  4. Ozempic $273 19 payments
  5. FARXIGA $206 10 payments
  6. AIMOVIG $165 12 payments
  7. TRULICITY $157 13 payments
  8. Kerendia $148 9 payments
  9. BREZTRI $132 7 payments
  10. EMGALITY $121 10 payments
  11. Other $2,569 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

429

Median for Internal Medicine: 777

Drug cost

$19,394

Median for Internal Medicine: $73,373

Branded share of claims

17.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $15,745
Levothyroxine Sodium Generic 40 $398
Omeprazole Generic 22 $342
Gabapentin Generic 22 $334
Amlodipine Besylate Generic 35 $256
Rosuvastatin Calcium Generic 23 $236
Duloxetine Hcl Generic 17 $228
Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide Brand 27 $209
Atorvastatin Calcium Generic 25 $195
Lovastatin Generic 17 $194

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record